To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 175 mg/m2) and carboplatin in subjects with advanced solid tumors Assessed at periodic visits [clinicaltrials_resource:555f6e732052c52886d428da58c5d7b1]
Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
To evaluate the safety, tolerability, and MTD of XL147 administered in combination with paclitaxel (at doses up to 175 mg/m2) and carboplatin in subjects with advanced solid tumors Assessed at periodic visits [clinicaltrials_resource:555f6e732052c52886d428da58c5d7b1]
Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
Bio2RDF identifier
555f6e732052c52886d428da58c5d7b1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:555f6e732052c52886d428da58c5d7b1
measure [clinicaltrials_vocabulary:measure]
To evaluate the safety, tolera ...... cts with advanced solid tumors
time frame [clinicaltrials_vocabulary:time-frame]
Assessed at periodic visits
description
Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
identifier
clinicaltrials_resource:555f6e732052c52886d428da58c5d7b1
title
To evaluate the safety, tolera ...... rs Assessed at periodic visits
@en
type
label
To evaluate the safety, tolera ...... f6e732052c52886d428da58c5d7b1]
@en